DCO

Beneath an ugly headline, Ducommun's core business is improving. Revenue has compounded steadily from $645M (FY2021) to $825M (FY2025, +4.9% YoY), and gross profit actually rose +12.3% to $222M with gross margin expanding to 26.9% — operations are getting better, not worse. The FY2025 net loss of -$33.9M (EPS -$2.27) and operating loss of -$32.3M are not a collapse in the franchise: the 10-K explicitly ties the jump in long-term debt (+30.1% to $300M) to 'litigation settlement and related costs, net during the fourth quarter of 2025.' That same charge drove operating cash flow to -$33.4M. Strip the settlement and this looks much like FY2024, which earned $31.5M. Liquidity and leverage remain sound: current assets of $626M cover current liabilities of $179M (3.5x), and liabilities/equity is a modest 0.79x against $662M of equity.

The problem is what you pay for it. At $184.42 the stock carries a $2.76B market cap, 3.4x trailing sales — a full multiple for a contract aerospace-parts manufacturer building mostly firm-fixed-price work (per the MD&A revenue-recognition discussion), where margins are structurally capped and contracts carry termination-for-convenience clauses. There is no meaningful P/E to anchor to because GAAP earnings are negative this year, and the company pays no dividend, so the entire case rests on normalized earnings power that the litigation has obscured. The shares are up +3.81% today and the market is clearly already crediting a clean post-settlement reset.